Hexagon Bio is a drug discovery company enabled by a novel understanding of natural product evolution. Hexagon's highly interdisciplinary platform uses data science, genomics, synthetic biology and automation to discover potent, evolutionarily refined small molecules and their protein targets directly from fungal genomes. Hexagon develops these molecules into therapeutics to combat human disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/15/20 | $47,000,000 | Series A |
The Column Group Two Sigma Ventures | undisclosed |
| 02/13/23 | $77,300,000 | Series B |
8VC Canada Pension Plan Investment Board Nextech Ventures The Column Group Two Sigma Ventures | undisclosed |
